{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:31:36Z","timestamp":1787574696558,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Korean Society of Hematology","award":["ICKSH-2022-07"],"award-info":[{"award-number":["ICKSH-2022-07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00162-1","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:13:44Z","timestamp":1787573624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting CDK7 to overcome hypomethylating agent resistance in acute myeloid leukemia"],"prefix":"10.1007","volume":"61","author":[{"given":"Bon-Kwan","family":"Koo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ji","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunkyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Young","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Seung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Hye","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"9","key":"162_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/leu.2013.173","volume":"27","author":"EH Estey","year":"2013","unstructured":"Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013;27(9):1803\u201312.","journal-title":"Leukemia"},{"issue":"1","key":"162_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.18632\/oncotarget.1319","volume":"5","author":"CT Tsai","year":"2014","unstructured":"Tsai CT, Yang PM, Chern TR, Chuang SH, Lin JH, Klemm L, et al. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget. 2014;5(1):211\u201323.","journal-title":"Oncotarget"},{"issue":"3","key":"162_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","volume":"113","author":"T Qin","year":"2009","unstructured":"Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2\u2019-deoxycytidine in human cancer cell lines. Blood. 2009;113(3):659\u201367.","journal-title":"Blood"},{"issue":"4","key":"162_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.exphem.2013.12.004","volume":"42","author":"P Sripayap","year":"2014","unstructured":"Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K, et al. Mechanisms of resistance to azacitidine in human leukemia cell lines. Exp Hematol. 2014;42(4):294-306.e2.","journal-title":"Exp Hematol"},{"issue":"7","key":"162_CR5","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873\u201389.","journal-title":"Leukemia"},{"issue":"12","key":"162_CR6","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1158\/1078-0432.CCR-16-2304","volume":"23","author":"F Solly","year":"2017","unstructured":"Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, et al. An miRNA-DNMT1 axis is involved in azacitidine resistance and predicts survival in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia. Clin Cancer Res. 2017;23(12):3025\u201334.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"162_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","volume":"20","author":"A Unnikrishnan","year":"2017","unstructured":"Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, et al. Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep. 2017;20(3):572\u201385.","journal-title":"Cell Rep"},{"issue":"4","key":"162_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","volume":"35","author":"X Gu","year":"2021","unstructured":"Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, et al. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia. 2021;35(4):1023\u201336.","journal-title":"Leukemia"},{"issue":"14","key":"162_CR9","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1021\/acs.jmedchem.9b01985","volume":"63","author":"S Diab","year":"2020","unstructured":"Diab S, Yu M, Wang S. CDK7 inhibitors in cancer therapy: the sweet smell of success? J Med Chem. 2020;63(14):7458\u201374.","journal-title":"J Med Chem"},{"issue":"11","key":"162_CR10","first-page":"3664","volume":"10","author":"JR Huang","year":"2018","unstructured":"Huang JR, Qin WM, Wang K, Fu DR, Zhang WJ, Jiang QW, et al. Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo. Am J Transl Res. 2018;10(11):3664\u201376.","journal-title":"Am J Transl Res"},{"issue":"6","key":"162_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41422-018-0020-z","volume":"28","author":"C Wang","year":"2018","unstructured":"Wang C, Jin H, Gao D, Wang L, Evers B, Xue Z, et al. A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell Res. 2018;28(6):690\u20132.","journal-title":"Cell Res"},{"issue":"8","key":"162_CR12","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41418-018-0222-4","volume":"26","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Lu L, Jiang G, Chen Z, Li J, An P, et al. Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer. Cell Death Differ. 2019;26(8):1442\u201352.","journal-title":"Cell Death Differ"},{"issue":"1","key":"162_CR13","doi-asserted-by":"publisher","first-page":"14290","DOI":"10.1038\/ncomms14290","volume":"8","author":"F Cayrol","year":"2017","unstructured":"Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun. 2017;8(1):14290.","journal-title":"Nat Commun"},{"key":"162_CR14","first-page":"2645","volume":"130","author":"K Clark","year":"2017","unstructured":"Clark K, Ainscow E, Peall A, Thomson S, Leishman A, Elaine S, et al. CT7001, a novel orally bio-available CDK7 inhibitor, is highly active in in-vitro and in-vivo models of AML. Blood. 2017;130:2645.","journal-title":"Blood"},{"issue":"13","key":"162_CR15","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","volume":"79","author":"S Hu","year":"2019","unstructured":"Hu S, Marineau JJ, Rajagopal N, Hamman KB, Choi YJ, Schmidt DR, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Can Res. 2019;79(13):3479\u201391.","journal-title":"Can Res"},{"issue":"10","key":"162_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11004","volume":"8","author":"BK Koo","year":"2022","unstructured":"Koo BK, Choi EJ, Hur EH, Moon JH, Kim JY, Park HS, et al. Antileukemic activity of YPN-005, a CDK7 inhibitor, inducing apoptosis through c-MYC and FLT3 suppression in acute myeloid leukemia. Heliyon. 2022;8(10):e11004.","journal-title":"Heliyon"},{"issue":"7","key":"162_CR17","doi-asserted-by":"publisher","first-page":"11748","DOI":"10.18632\/oncotarget.14342","volume":"8","author":"EH Hur","year":"2017","unstructured":"Hur EH, Jung SH, Goo BK, Moon J, Choi Y, Choi DR, et al. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM\/AZA-1 and MOLM\/DEC-5. Oncotarget. 2017;8(7):11748\u201362.","journal-title":"Oncotarget"},{"issue":"3","key":"162_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4062\/biomolther.2022.117","volume":"31","author":"EJ Choi","year":"2023","unstructured":"Choi EJ, Koo BK, Hur EH, Moon JH, Kim JY, Park HS, et al. Inhibition of DNMT3B and PI3K\/AKT\/mTOR and ERK pathways as a novel mechanism of volasertib on hypomethylating agent-resistant cells. Biomol Ther (Seoul). 2023;31(3):319\u201329.","journal-title":"Biomol Ther (Seoul)"},{"issue":"2","key":"162_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93\u2013115.","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"162_CR20","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1128\/MCB.00857-06","volume":"27","author":"J Fu","year":"2007","unstructured":"Fu J, Yoon HG, Qin J, Wong J. Regulation of P-TEFb elongation complex activity by CDK9 acetylation. Mol Cell Biol. 2007;27(13):4641\u201351.","journal-title":"Mol Cell Biol"},{"issue":"5297","key":"162_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.275.5297.200","volume":"275","author":"G Natoli","year":"1997","unstructured":"Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, et al. Activation of SAPK\/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science. 1997;275(5297):200\u20133.","journal-title":"Science"},{"issue":"5229","key":"162_CR22","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1126\/science.7544915","volume":"269","author":"M Rothe","year":"1995","unstructured":"Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 1995;269(5229):1424\u20137.","journal-title":"Science"},{"issue":"4","key":"162_CR23","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1073\/pnas.96.4.1234","volume":"96","author":"N Tsukamoto","year":"1999","unstructured":"Tsukamoto N, Kobayashi N, Azuma S, Yamamoto T, Inoue J. Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40. Proc Natl Acad Sci U S A. 1999;96(4):1234\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"162_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.cgt.7700527","volume":"10","author":"AW Tong","year":"2003","unstructured":"Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10(1):1\u201313.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"162_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01442-3","volume":"20","author":"C Yan","year":"2021","unstructured":"Yan C, Richmond A. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy. Mol Cancer. 2021;20(1):146.","journal-title":"Mol Cancer"},{"issue":"1","key":"162_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152\u201372.","journal-title":"Immunol Rev"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00162-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:13:46Z","timestamp":1787573626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00162-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00162-1","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests relevant to the contents of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"45"}}